There are 2 papers on non-fatal cardiovascular events in aging research: 1 trial and 1 observational study in people.
2 papers study it20 more mention it2 findings
5 new papers in 30 daysSee all 22 papers on non-fatal cardiovascular events
“The combination group displayed the lowest risk for developing the composite outcome of non-fatal cardiovascular events after adjusting for age, sex, hypertension, hyperlipidemia, smoking and CAD”
- Human trial1
- Humans1
Interventions
1Finerenone
downin humans1
1 study
Finerenone
downin humans1
Finerenone decreases non-fatal cardiovascular events in humans (Base-model HRs: low tertile 0.89 (95% CI 0.60–1.32), intermediate 1.11 (0.79–1.56), high 0.85 (0.65–1.11); interaction p=0.57).
“Finerenone demonstrated consistent CV benefit across AHA PREVENTTM-estimated risk levels.”
Human trialType 2 diabetes and chronic kidney disease without prior cardiovascular disease; comparison with placebo across baseline PREVENT risk tertilesn = 7,050
AHA Scientific Sessions 2026 abstract
Associations
1Liraglutide + empagliflozin
downin humans1HR 4.36
1 study
Liraglutide + empagliflozin
downin humans1HR 4.36
Liraglutide + empagliflozin is linked with a lower risk of non-fatal cardiovascular events in humans (HR=4.36, 95%CI 2.04-9.33 (insulin vs combination); HR=2.45 for GLP1-RA and HR=3.07 for SGLT2i vs combination).
“The combination group displayed the lowest risk for developing the composite outcome of non-fatal cardiovascular events after adjusting for age, sex, hypertension, hyperlipidemia, smoking and CAD”
Humansadjusted for age, sex, hypertension, hyperlipidemia, smoking and CAD; effect shown as insulin vs combination HRmedian follow-up 69 months
ESC Congress 2026 abstract